Figure 3 Clinical translation and human data taxonomy The translation of these mechanisms into human clinical data requires a strict evidence taxonomy to avoid conflating metabolic improvements with intrinsic disease modification
The rise corresponds with the established effectiveness of GLP-1 RAs, such as semaglutide and liraglutide, for significant weight loss in people with obesity a group representing roughly 93 million potentially eligible U.S
Residents in Mandeville, Louisiana, may qualify for semaglutide weight loss with a BMI of 30 or higher, or a BMI of 27 or more with related medical issues such as hypertension, type 2 diabetes, or elevated cholesterol levels
Document changes not just in A1C and weight but also patientreported changes in appetite, cravings, and lifestyle habits, including alcohol consumption
Image: 3dfoto/Getty Images About the Author Matthew Solan, Former Executive Editor, Harvard Men's Health Watch About the Reviewer Howard E
Corinne at Legacy Physicians.